----
Current ValuationThe current P/E ratio is -0.92, within the reasonable range, cheaper than 52.72% of the time in the past 5 years, and the industry ranks 79/173, the industry Median -0.92.
-0.922xP/E
$14.10Stock price
$-15.29Earnings per share
-0.922xP/E
Stock price$14.10Earnings per share$-15.29
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.83x
- Typical range
- -1.67x–8.23x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
012243648
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAXUSBaxter | -12.11x | 141.71% | $12.87B |
GKOSUSGlaukos | -51.91x | 75.37% | $9.76B |
TFXUSTeleflex | -5.11x | 118.39% | $5.27B |
IRTCUSIRhythm | -254.57x | 70.88% | $3.55B |
PLSEUSPulse Biosciences | -43.24x | 26.85% | $3.46B |
BFLYUSButterfly Network | -28.82x | 31.45% | $2.16B |
AXGNUSAxogen | -63.26x | 15.29% | $2.12B |
ASSTUSStrive | -1.96x | 63.23% | $1.91B |
ATECUSAlphatec | -15.19x | 41.67% | $1.67B |
NVCRUSNovocure | -11.21x | 1.23% | $1.67B |
KMTSUSKestra Medical Tech | -10.55x | 0.94% | $1.58B |
DRTSUSAlpha Tau Medical | -13.70x | -- | $1.27B |
TNDMUSTandem Diabetes | -18.30x | 77.60% | $1.16B |
ENOVUSEnovis | -0.99x | 100.97% | $1.10B |
PRCTUSPROCEPT BioRobotics | -9.97x | 3.47% | $1.09B |
IARTUSIntegra LifeSciences | -148.84x | 109.42% | $1.08B |
AORTUSArtivion | -326.37x | 266.67% | $1.04B |
CBLLUSCeribell | -15.20x | 35.15% | $1.00B |
QDELUSQuidelOrtho | -0.92x | 75.33% | $966.91M |
BBNXUSBeta Bionics | -12.76x | 11.45% | $931.23M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
